Stemina biomarker discovery

Regenerative Medicine
G G Cezar, E L R Donley

Abstract

Stemina Biomarker Discovery was established in 2006 to commercialize technology developed by Dr Gabriela Cezar at the University of Wisconsin (WI, USA). Stemina's cell-based assays arise from the strategic convergence of two cutting edge technologies: metabolomics and human embryonic stem (hES) cells. Stemina analyzes the small molecules secreted by hES cells and differentiated cell types such as neural and heart cells derived from hES cells by liquid chromatography mass spectrometry at its state-of-the-art facilities in Madison, WI, USA. Stemina's first technology platform has identified a dynamic set of small molecules in the extracellular secretome of hES cells secreted in response to exposure to a library of known teratogens. Alterations to small molecules in the biochemical pathway(s) of hES cells are mapped in silico to identify biomarkers of toxicity for drug screening and development in an all human system. These small human molecules may then be translated in vivo as biomarkers of toxic response and disease.

References

Sep 1, 1988·Teratology·W Lenz
Feb 1, 2000·Molecular Medicine Today·R GoldK V Toyka
Sep 11, 2002·Obstetrics and Gynecology·W Y Lo, J M Friedman
Aug 24, 1962·Ugeskrift for laeger·S THIELE
Nov 29, 2007·Stem Cells and Development·Gabriela G CezarAlysson R Muotri

❮ Previous
Next ❯

Citations

Nov 23, 2011·Biomarkers in Medicine·Clifford D L FolmesAndre Terzic
Mar 23, 2012·Brazilian Journal of Biology = Revista Brasleira De Biologia·R G BotelhoJ B Santos
Sep 14, 2010·Memórias do Instituto Oswaldo Cruz·Fernanda CarregaroAndréia M Leopoldino

❮ Previous
Next ❯

Methods Mentioned

BETA
metabolomic profiling

Software Mentioned

Stemina

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.